Skip to main content

Par Pharmaceutical Resumes Generic Flonase Sales

A Maryland court denies an injunction sought by GlaxoSmithKline.

Par Pharmaceutical

(PRX)

announced Tuesday that it resumed shipment of fluticasone propionate nasal spray, a substitute for

GlaxoSmithKline's

>

(GSK) - Get GlaxoSmithKline Plc Report

Scroll to Continue

TheStreet Recommends

Flonase.

Par had stopped all shipments since Feb. 23 after a temporary restraining order was granted to GSK by the U.S. District Court for the District of Maryland.

On Monday evening, the court denied GlaxoSmithKline's motion to set aside the Food and Drug Administration's approval of the generic spray, and the restraining order was allowed to expire.

Annual sales of Flonase in the U.S. exceed $900 million.

Shares of Par Pharmaceutical rose 32 cents, or 1.1%, to $28.99 Tuesday.

This story was created through a joint venture between TheStreet.com and IRIS.